Clinical Trials
51 trialsStudy of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
PRO1107 in Patients With Advanced Solid Tumors
Genmab
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
ARTIST
Artios Pharma Ltd
PAVO
Tempus AI
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Alaunos Therapeutics
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
START
Lyell Immunopharma, Inc.
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
C4431001
Pfizer
MasterKey-01
Black Diamond Therapeutics, Inc.
A Study of SGN-ALPV in Advanced Solid Tumors
Seagen Inc.
A Study of SGN-STNV in Advanced Solid Tumors
Seagen Inc.
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
FPA150-001
Five Prime Therapeutics, Inc.
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
A Study of DeTIL-0255 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
LODESTAR
pharmaand GmbH
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Xenetic Biosciences, Inc.
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Zai Lab (Hong Kong), Ltd.
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Novartis
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
PharmaMar
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
AL3818
Advenchen Laboratories, LLC
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
AbbVie
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
Ipsen
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
IXAMPLE2
R-Pharm
SIGNATURE
Novartis
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Otsuka Novel Products GmbH
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
CytoCore, Inc.
Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
Cook Group Incorporated
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals